Results 121 to 130 of about 41,337 (280)

MPN-Unclassified

Cancer Research, Statistics, and Treatment, 2022
Suvir Singh, Kunal Jain
openaire   +1 more source

p53 at the crossroads of MPN treatment

Blood, 2014
In this issue of Blood, Lu et al describe the cooperation between an orally bioavailable mouse double minute 2 (MDM2) antagonist (RG7112) and the pegylated interferon α (Peg-IFNα 2a) to target JAK2V617F hematopoietic progenitors and stem cells. Their work provides a rationale for the treatment of patients suffering from myeloproliferative neoplasms ...
openaire   +3 more sources

Evaluation de trois méthodes de détection et de dénombrement des bactéries nitratantes et de Nitrobacter dans les sédiments d'eau douce (MPN-PCR, MPN-griess, immunofluorescence)

, 1999
[Departement_IRSTEA]GMA [TR1_IRSTEA]12 - MILEAU / EXPERInternational audienceNitrification in freshwater, a key process in the nitrogen cycle, is now well known to take place predominantly on suspended particles and in sediment.
Degrange, Valérie, Volat, B., Clays-Josserand, Annie, Feray, C., Montuelle, Bernard   +4 more
core  

An international consortium proposal of uniform response criteria for myelodysplastic/myeloproliferative neoplasms (MDS/MPN) in adults

, 2015
MDS/MPN are hematologically diverse stem cell malignancies sharing phenotypic features of both myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN).
List, Alan F, Komrokji, Rami, Garcia-Manero, Guillermo, Solary, E., Maciejewski, Jaroslaw Pawel, Padron, E., Savona, Michael, Cross, N.C.P., Tiu, Ramon V., Itzykson, R., Mughal, Tariq I., Tiu, Ramon, Gerds, A., Sanz, Guillermo, Mughal, T.I., Savona, M.R., Cervantes, Francisco, Mesa, R., Tiu, R.V., Fenaux, P., Maciejewski, Jaroslaw, Mesa, Ruben, List, Alan, Cervantes, F., Niemeyer, Charlotte Marie, Cazzola, M., Mughal, Tariq, Orazi, A., Itzykson, Raphael, Cross, Nicholas C. P., Malcovati, L., Savona, Michael R., Padron, Eric, Niemeyer, C.M., Sanz, G., Fenaux, Pierre, Germing, U., Tibes, Raoul, Orazi, Attilio, Komrokji, R., Garcia-Manero, G., Tibes, R., Kiladjian, Jean-Jacques, Maciejewski, J., List, A.F., Niemeyer, Charlotte, Kiladjian, J.-J., Solary, Éric, MDS/MPN International Working Group, [Study group], Germing, Ulrich, Cross, Nicholas, Gerds, Aaron, Kiladjian JJ, Tibes R, Garcia Manero G, Gerds A, Mesa R, Maciejewski J, Padron E, Mughal TI, Cazzola M, Niemeyer CM, Cervantes F, Germing U, Savona MR, Tiu RV, Solary E, Itzykson R, MALCOVATI, LUCA, Sanz G, Fenaux P, CAZZOLA, MARIO, List AF, Cross NC, Komrokji R, List AFSavona MR, Orazi A, Malcovati L   +77 more
core   +1 more source

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera

British Journal of Haematology, EarlyView.
In patients with essential thrombocythaemia or polycythaemia vera, higher estimated pulse wave velocity (ePWV) was independently associated with major adverse cardiovascular events, while its relationship with overall survival was largely age‐driven.
Alessandro Costa, Olga Mulas, Federica Pilo, Eleonora Atzeni, Martina Pettinau, Daniela Mantovani, Giovanni Caocci   +6 more
wiley   +1 more source

Increase in fetal haemoglobin from baseline to day 10 is a biomarker for response to decitabine in AML: Results of the AML21 randomized phase III trial of the EORTC Leukemia Group, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) and German MDS Study Group

British Journal of Haematology, EarlyView.
Summary Lack of response or delayed response to therapy are major challenges in the use of DNA‐hypomethylating agents (HMA) in patients with acute myeloid leukaemia (AML). Fetal haemoglobin (HbF) is a potential biomarker for response to HMA treatment but has only been studied in small single‐centre studies.
Julia Stomper, Michal Kicinski, Tobias Ma, Thomas Meyer, Sylvain Chantepie, Richard Noppeney, Mario Luppi, Ernesta Audisio, Laimonas Griškevičius, Andreas Neubauer, Robin Foà, Walter J. F. M. Van der Velden, Anna Candoni, Radovan Vrhovac, Gianluca Gaidano, Catharina Van Elssen, Mels Hoogendoorn, Maurizio Musso, Attilio Olivieri, Christian Junghanß, Emmanuel Bissé, Stephanie Antunes, Frédéric Baron, Adriano Venditti, Joop H. Jansen, Pierre W. Wijermans, Gerwin Huls, Michael Lübbert   +27 more
wiley   +1 more source

Updates in acute graft‐versus‐host disease: From novel pathogenic mechanisms to emerging therapeutic targets

British Journal of Haematology, EarlyView.
The graphical abstract provides a view on selected aspects of the pathogenesis, risk stratification and treatment of acute GVHD. Summary Acute graft‐versus‐host disease (aGVHD) remains a major complication following allogeneic haematopoietic stem cell transplantation (allo‐HSCT), representing a leading cause of non‐relapse mortality (NRM) and ...
Hazim Khatib, Robert Zeiser
wiley   +1 more source

P1035: RING SIDEROBLASTS <15% WAS AN INDEPENDENT RISK FACTOR FOR MYELODYSPLASTIC/MYELOPROLIFERATIVE NEOPLASM WITH SF3B1 MUTATION AND THROMBOCYTOSIS

HemaSphere, 2023
Fuhui LI, Zhijian Xiao, Zefeng Xu
doaj   +1 more source

Dietary Leucine Restriction Suppresses Platelet‐Driven HCC Growth by Attenuating mTOR Signaling

Cancer Science, EarlyView.
Platelets induce leucine accumulation in HCC cells. In vitro, leucine deprivation or S6K1 inhibition with PF‐4708671 suppresses platelet‐promoted proliferation, migration, and invasion. In vivo, dietary leucine restriction reduces tumor growth following platelet pre‐incubation.
Xeulian Ruan, Guiyong Ou, Cuiju Mo, Yi Zhang, Shanzi Qin, Yongling Chen, Dan Li, Liuying Nie, Li Xie, Zuojian Hu   +9 more
wiley   +1 more source

T‐Cell Response After SARS‐CoV‐2 Vaccination in Patients With Hematological Malignancy

European Journal of Haematology, EarlyView.
ABSTRACT Patients with hematologic malignancies (HM) often mount poor humoral responses to SARS‐CoV‐2 vaccination due to their immunocompromised status. Protection against severe COVID‐19 is strongly related to cellular immunity, yet vaccine‐induced T‐cell responses remain incompletely characterized.
L. S. Boerenkamp, N. Scheffers, L. Brandts, G. N. Y. van Gorkom, C. R. Pothast, M. H. M. Heemskerk, L. Wieten, C. H. M. J. Van Elssen   +7 more
wiley   +1 more source